Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Unilateral Subjective Tinnitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Gacyclidine (Primary)
- Indications Tinnitus
- Focus Therapeutic Use
- Sponsors Otonomy [CEASED]
- 01 Aug 2022 Primary endpoint (Change from Baseline in Tinnitus Functional Index (TFI)) has not been met as per results published in the Otonomy Media Release
- 01 Aug 2022 Results published in the Otonomy Media Release
- 30 Jun 2022 Status changed from active, no longer recruiting to completed.